Expression of ASBT and ASGPR mediated receptors for oral liver-targeting preparations in a rat model of hepatic alveolar echinococcosis

Ruixue GAO; Chunhui HU; Fabin ZHANG; Pan GAO; Xuehui GAN; Yaogang ZHANG; Bofan JIANG

doi:10.3969/j.issn.1001-5256.2021.04.024

Volume 37 Issue 4

Apr. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(4): 846-851

PDF( 3653 KB)

Expression of ASBT and ASGPR mediated receptors for oral liver-targeting preparations in a rat model of hepatic alveolar echinococcosis

DOI: 10.3969/j.issn.1001-5256.2021.04.024

1.
Medical College of Qinghai University, Xining 810001, China
2.
Qinghai Province Key Laboratory of Hydatid Disease Research, Xining 810001, China

Received Date: 2020-09-12
Accepted Date: 2020-11-25
Published Date: 2021-04-20

Abstract

Abstract

Objective To investigate the feasibility of apical sodium-dependent bile salt transporter (ASBT) and asialoglycoprotein receptor (ASGPR) in the design of oral liver-targeting preparations for the treatment of hepatic alveolar echinococcosis (HAE) by measuring the expression of ASBT and ASGPR. Methods A total of 18 male Sprague-Dawley rats were selected, among which 10 were used to establish a model of HAE (HAE group) and 8 were used as controls (normal group). Immunofluorescence assay, Western blotting, and quantitative real-time PCR were used to measure the expression distribution, protein expression level, and mRNA expression level of ASBT in the ileal tissue of HAE model rats and normal rats; the same methods were used to measure the expression level of ASGPR in the non-diseased liver tissue and the marginal zone of liver tissue lesion of HAE model rats and the liver tissue of normal rats. The t-test was used for comparison of normally distributed continuous data between two groups; a one-way analysis of variance was used for comparison between three groups, and the least significant difference t-test was used for comparison between two groups. Results The results of immunofluorescence assay, Western blotting, and quantitative real-time PCR showed that compared with the normal group, the HAE group had significantly upregulated expression of ASBT in the ileal tissue (t=5.309, 4.110, and 28.060, all P < 0.05) and a significantly higher expression level of ASGPR (the closer to the lesion, the higher the expression) (F=110.666, 128.201, and 143.879, all P < 0.001). Conclusion ASBT and ASGPR can be used as potential mediated receptors for oral liver-targeting preparations for HAE, which provides a theoretical basis for the design of oral liver-targeting preparations for the treatment of HAE.
- Echinococcosis, Hepatic,
- Molecular Targeted Therapy,
- Apical Sodium-Dependent Bile Salt Transporter,
- Asialoglycoprotein Receptor,
- Rats, Sprague-Dawley

FullText(HTML)

References(26)

References

[1]	ROMIG T, EBI D, WASSERMANN M. Taxonomy and molecular epidemiology of Echinococcus granulosus sensu lato[J]. Vet Parasitol, 2015, 213(3-4): 76-84. DOI: 10.1016/j.vetpar.2015.07.035
[2]	ZHANG W, ZHANG Z, WU W, et al. Epidemiology and control of echinococcosis in central Asia, with particular reference to the People's Republic of China[J]. Acta Trop, 2015, 141(Pt B): 235-243. http://smartsearch.nstl.gov.cn/paper_detail.html?id=ec4b630bb5cadfb9efc52d18b4fbd4f0
[3]	ZHANG MY, WU WP, GUAN YY, et al. Analysis on disease burden of hydatid disease in China[J]. Chin J Parasitol Parasitic Dis, 2018, 36(1): 15-19, 25. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB201801005.htm 张梦媛, 伍卫平, 官亚宜, 等. 我国棘球蚴病疾病负担分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(1): 15-19, 25. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB201801005.htm
[4]	AILIYALI AL, AYXAMGUL ALMS, GUO M, et al. Awareness rate of core knowledge of echinococcosis prevention and control in residents of Chinese farming and pastoral areas—meta-analysis[J]. Chin J Zoonoses, 2019, 35(2): 1144-1149. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZRSZ201912015.htm 艾力亚力·艾力, 阿依谢姆古丽·阿力马斯, 郭敏, 等. 中国包虫病流行区居民包虫病防治知识知晓率—Meta分析[J]. 中国人兽共患病学报, 2019, 35(2): 1144-1149. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRSZ201912015.htm
[5]	CHEN ZY. Surgical treatment of complicated liver hydatid disease[J]. Chin J Bases Clin Gen Surg, 2017, 24(7): 785-787. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201707001.htm 陈哲宇. 复杂肝包虫病的外科治疗[J]. 中国普外基础与临床杂志, 2017, 24(7): 785-787. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWL201707001.htm
[6]	ABUDUAINI ABLZ, WEN H. Advances in multidisciplinary individualized treatment of refractory hepatic alveolar echinococcosis[J]. J Clin Hepatol, 2015, 31(4): 639-641. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2015.04.040 阿卜杜艾尼·啊卜力孜, 温浩. 难治性肝泡型包虫病的多学科个体化治疗[J]. 临床肝胆病杂志, 2015, 31(4): 639-641. DOI: 10.3969/j.issn.1001-5256.2015.04.040
[7]	CHAI JJ, MENGHEBT, JIAO W, et al. Clinical efficacy of albendazole emulsion in treatment of 212 cases of liver cystic hydatidosis[J]. Chin J Parasitol Parasitic Dis, 2001, 19(3): 3-8. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB200103000.htm 柴君杰, 孟贺巴特, 焦伟, 等. 阿苯达唑乳剂治疗肝囊型包虫病212例临床疗效观察[J]. 中国寄生虫学与寄生虫病杂志, 2001, 19(3): 3-8. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJSB200103000.htm
[8]	ZHANG XN, ZHANG Q, WEN H, et al. Studies on preparation of albendazole polybutycyanocrylate nanoparticles and its stability[J]. Chin Pharmacol J, 2003, 38(5): 37-39. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX200305013.htm 张学农, 张强, 温浩, 等. 乳化聚合法制备阿苯达唑聚氰基丙烯酸酯纳米球的方法比较及稳定性考察[J]. 中国药学杂志, 2003, 38(5): 37-39. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX200305013.htm
[9]	GUO F, DONG D, CHEN CZ, et al. Observation on nano albendazole against echinococcus granulosus protoscolices[J]. J Shihezi Univ(Natural Sci), 2018, 36(4): 482-485. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-SHZN201804014.htm 郭峰, 董丹, 陈聪哲, 等. 纳米化阿苯达唑对细粒棘球蚴原头节生长的影响[J]. 石河子大学学报(自然科学版), 2018, 36(4): 482-485. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZN201804014.htm
[10]	LI M, WANG Q, LI Y, et al. Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges[J]. Pharmacol Ther, 2020, 212: 107539. DOI: 10.1016/j.pharmthera.2020.107539
[11]	FAN WW. Design of novel oral insulin nanocarriers to achieve highly efficient delivery in vivo and the underlying mechanism[D]. Shanghai: University of Chinese Academy of Sciences (Shanghai Institute of Materia Medica, Chinese Academy of Sciences), 2019. (in Chinese) 范未伟. 胰岛素新型口服纳米载体的设计及其体内高效递送机制的研究[D]. 上海: 中国科学院大学(中国科学院上海药物研究所), 2019.
[12]	XUE Y, MA C, HANNA I, et al. Intestinal transporter-associated drug absorption and toxicity[J]. Adv Exp Med Biol, 2019, 1141: 361-405. http://www.ncbi.nlm.nih.gov/pubmed/31571170
[13]	ZHANG Y, ZHANG X, ZENG C, et al. Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR)[J]. Bioorg Med Chem, 2019, 27(11): 2187-2191. DOI: 10.1016/j.bmc.2019.04.019
[14]	WANG Z, XU J, WANG HJ, et al. Establishment of animal model for Echinococcus inoculation infection in Microtus fuscus in Qinghai-Tibet Plateau[J]. J Clin Hepatol, 2018, 34(2): 373-377. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.02.031 王展, 胥瑾, 王海久, 等. 泡球蚴感染青藏高原野生田鼠动物模型的建立[J]. 临床肝胆病杂志, 2018, 34(2): 373-377. DOI: 10.3969/j.issn.1001-5256.2018.02.031
[15]	MAIMAITI WSL, TUERGANAILI AJ. Research advances in surgical treatment of hepatic alveolar echinococcosis[J]. J Clin Hepatol, 2018, 34(3): 645-648. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.03.046 买买提·瓦司力, 吐尔干艾力·阿吉. 肝泡型包虫病的手术治疗进展[J]. 临床肝胆病杂志, 2018, 34(3): 645-648. DOI: 10.3969/j.issn.1001-5256.2018.03.046
[16]	MOVAHEDI F, LI L, GU W, et al. Nanoformulations of albendazole as effective anticancer and antiparasite agents[J]. Nanomedicine (Lond), 2017, 12(20): 2555-2574. DOI: 10.2217/nnm-2017-0102
[17]	YIN J, FAN HN, WEN H, et al. Current status of the research and development of new formulations and drugs for cystic echinococcosis[J]. J Clin Hepatol, 2019, 35(4): 908-912. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.04.045 尹杰, 樊海宁, 温浩, 等. 囊型包虫病药物新剂型研发及新药开发现状[J]. 临床肝胆病杂志, 2019, 35(4): 908-912. DOI: 10.3969/j.issn.1001-5256.2019.04.045
[18]	CHAI J, MENGHEBAT, WEI J, et al. Observations on clinical efficacy of albendazole emulsion in 264 cases of hepatic cystic echinococcosis[J]. Parasitol Int, 2004, 53(1): 3-10. DOI: 10.1016/j.parint.2003.09.015
[19]	LI H, SONG T, SHAO Y, et al. Comparative evaluation of liposomal albendazole and tablet-albendazole against hepatic cystic echinococcosis: A non-randomized clinical trial[J]. Medicine (Baltimore), 2016, 95(4): e2237. DOI: 10.1097/MD.0000000000002237
[20]	LIU Y, WANG XQ, REN WX, et al. Novel albendazole-chitosan nanoparticles for intestinal absorption enhancement and hepatic targeting improvement in rats[J]. J Biomed Mater Res B Appl Biomater, 2013, 101(6): 998-1005. http://smartsearch.nstl.gov.cn/paper_detail.html?id=ac476a01c5990aa617c7d2a9088e6078
[21]	CHATURVEDI K, GANGULYK, KULKARNI AR, et al. Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles[J]. Nanomedicine (Lond), 2015, 10(10): 1569-1583. DOI: 10.2217/nnm.15.36
[22]	LOZANO E, MONTE MJ, BRIZ O, et al. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)[J]. J Control Release, 2015, 216: 93-102. DOI: 10.1016/j.jconrel.2015.08.022
[23]	MONESTIER M, CHARBONNIER P, GATEAU C, et al. ASGPR-mediated uptake of multivalent glycoconjugates for drug delivery in hepatocytes[J]. Chembiochem, 2016, 17(7): 590-594. DOI: 10.1002/cbic.201600023
[24]	D'SOUZA AA, DEVARAJAN PV. Asialoglycoprotein receptor mediated hepatocyte targeting-strategies and applications[J]. J Control Release, 2015, 203: 126-139. DOI: 10.1016/j.jconrel.2015.02.022
[25]	WANG K, XU J, LIU Y, et al. Self-assembled Angelica sinensis polysaccharide nanoparticles with an instinctive liver-targeting ability as a drug carrier for acute alcoholic liver damage protection[J]. Int J Pharm, 2020, 577: 118996. DOI: 10.1016/j.ijpharm.2019.118996
[26]	WU J, YUAN J, YE B, et al. Dual-responsive core crosslinking glycopolymer-drug conjugates nanoparticles for precise hepatocarcinoma therapy[J]. Front Pharmacol, 2018, 9: 663. DOI: 10.3389/fphar.2018.00663

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(6) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (573) PDF downloads(28)

Expression of ASBT and ASGPR mediated receptors for oral liver-targeting preparations in a rat model of hepatic alveolar echinococcosis

DOI: 10.3969/j.issn.1001-5256.2021.04.024

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expression of ASBT and ASGPR mediated receptors for oral liver-targeting preparations in a rat model of hepatic alveolar echinococcosis

DOI: 10.3969/j.issn.1001-5256.2021.04.024

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content